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background: Protease inhibitors (PIs) are known to increase LDL-C and have been associated with premature atherosclerosis. According to 
recent guidelines, some antiretroviral (ART) combinations are thought to have a safer cardiovascular profile than others and should be considered 
for patients with cardiac risk factors. Large randomized controlled trials are lacking, however, and the excess risk of cardiovascular events due to 
specific drug therapy is unknown.
objectives: Our aim was to explore whether one of two initial ART regimens was associated with more cardiovascular events. We compared the 
incidence and relative risks of heart failure (HF) and myocardial infarction in a cohort of HIV-infected patients at 1 and 5 years after the initiation of 
ART, and hypothesized that patients treated with PIs would have more events.
Methods: This is a longitudinal, descriptive study of a cohort of adult patients with HIV who were initially started on one of two regimens: Tenofovir/
Emtricitabine/Efavirenz (non-PI group) or Ritonavir-boosted Atazanavir + Tenofovir/Emtricitabine (PI group) from January 2006 to January 2013. RR 
and 95% CI were calculated as a measure of association between each covariate and the final outcome variable.
results: 1,625 patients were in the non-PI group and 1,177 in the PI group. The non-PI patients were older (45+/- 11 vs. 44+/-10 years, p = 
0.0137), had higher systolic blood pressures (119 +/- 6 mmHg vs. 117 +/- 6, p = 0.0001), higher LDLs (97 +/- 32 vs. 90 +/- 33, p < 0.0001), and 
had a similar prevalence of diabetes (8% vs. 7%, p= 0.6110). The cumulative incidence of myocardial infarction at 1 year was low and similar in 
both groups (non-PI 0.0% vs. PI 0.1%, RR 0.3186, CI 0.01,7.81, p = 0.4835). However, HF incidence was significantly higher in the PI group (2.1% vs. 
0.4%, RR 5.94, CI 2.9,11.8, p <0.0001). These findings were consistent at 5 years.
conclusions: There is a low short- and intermediate-term incidence of myocardial infarction in HIV patients receiving antiretroviral therapy, 
irrespective of the use of a PI. Our study demonstrates an unexpected increased risk for the development of HF associated with the use of a PI, 
which is not explained by baseline differences.
